Curis (CRIS): One Of The Most Compelling Risk/Rewards - RBC

October 12, 2016 9:24 AM EDT
Get Alerts CRIS Hot Sheet
Price: $3.04 +2.36%

Rating Summary:
    13 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade CRIS Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

RBC Capital analyst, Adnan Butt, reiterated his Outperform rating on shares of Curis (NASDAQ: CRIS) reiterating that the company is "one of the most compelling upside vs. downside opportunities" under coverage.

The analyst is awaiting data from a Phase 2 ‘907 study in MYC-driven DLBCL and from a Phase 1 CA-170 (oral checkpoint inhibitor) study by mid-2017. Positive data for either one should mean a big step-up in valuation and in-licensing CA-327 broadens the pipeline.

No change to the price target of $7.

For an analyst ratings summary and ratings history on Curis click here. For more ratings news on Curis click here.

Shares of Curis closed at $3.01 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

RBC Capital

Add Your Comment